551 related articles for article (PubMed ID: 27223147)
1. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
[TBL] [Abstract][Full Text] [Related]
2. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
[TBL] [Abstract][Full Text] [Related]
3. Factor VIII products and inhibitor development in severe hemophilia A.
Gouw SC; van der Bom JG; Ljung R; Escuriola C; Cid AR; Claeyssens-Donadel S; van Geet C; Kenet G; Mäkipernaa A; Molinari AC; Muntean W; Kobelt R; Rivard G; Santagostino E; Thomas A; van den Berg HM;
N Engl J Med; 2013 Jan; 368(3):231-9. PubMed ID: 23323899
[TBL] [Abstract][Full Text] [Related]
4. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
[TBL] [Abstract][Full Text] [Related]
5. Hemophilia Therapy--Navigating Speed Bumps on the Innovation Highway.
DiMichele DM
N Engl J Med; 2016 May; 374(21):2087-9. PubMed ID: 27223151
[No Abstract] [Full Text] [Related]
6. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
[TBL] [Abstract][Full Text] [Related]
8. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A.
Cannavò A; Valsecchi C; Garagiola I; Palla R; Mannucci PM; Rosendaal FR; Peyvandi F;
Blood; 2017 Mar; 129(10):1245-1250. PubMed ID: 28034891
[TBL] [Abstract][Full Text] [Related]
9. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Safety and Efficacy Data of a Plasma-Derived Factor VIII Concentrate with von Willebrand Factor for Treatment of Patients with Hemophilia A Covering 18 Years.
Kittler SFK; Miesbach W; Bauhofer A; Becker T; Schüttrumpf J; Dubovy P; Nemes L; Richter H; Königs C
Hamostaseologie; 2019 Nov; 39(4):360-367. PubMed ID: 31648354
[TBL] [Abstract][Full Text] [Related]
11. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
12. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
Oldenburg J; Lacroix-Desmazes S; Lillicrap D
Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
[TBL] [Abstract][Full Text] [Related]
13. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
Goudemand J
Haemophilia; 2007 Dec; 13 Suppl 5():47-51. PubMed ID: 18078397
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
16. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
[No Abstract] [Full Text] [Related]
17. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
18. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.
Collins PW; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Blood; 2014 Nov; 124(23):3389-97. PubMed ID: 25339360
[TBL] [Abstract][Full Text] [Related]
20. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
Gouw SC; van der Bom JG; Auerswald G; Ettinghausen CE; Tedgård U; van den Berg HM
Blood; 2007 Jun; 109(11):4693-7. PubMed ID: 17218379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
